Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765734 · ClinicalTrials.gov registry record · Phase 1
A Study of TAS3351 in NSCLC Patients With EGFRmt
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05765734 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 18 participants.
The verdict
NCT05765734, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in participants with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
Interventions
- DRUG TAS3351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05765734
The ClinicalTrials.gov registry entry for NCT05765734 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS3351 is the first listed.
NCT05765734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05765734 about?
NCT05765734 is a clinical study titled "A Study of TAS3351 in NSCLC Patients With EGFRmt". This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in participants with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
What is the current status of trial NCT05765734?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-05-25. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT05765734?
The interventions under investigation include: TAS3351 (DRUG).
Who is sponsoring clinical trial NCT05765734?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.